The year isn't over, either. A handful of closely watched drug applications remain under review. If approved — or, in one case, approved again — the drugs could bring in millions of dollars for their respective manufacturers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,